Skip to content
★ Sign in to follow
SR

Sven Rohmann

Oasmia Pharmaceutical AB
Total declarations
11
Company
1
▲ Purchases (4 ops.)
€137k
▼ Sales (6 ops.)
€291k

Latest filing published 22 Jun 2020 for Oasmia Pharmaceutical AB, €59k.

Filing timeline

BuySale
Sven Rohmann

Insider track record

Disclosed buys
4
Disclosed sells
6
Signal history

Closed purchases

Market purchases
4

Not enough history yet: 0 closed purchases, at least 2 are needed.

Purchases by company

Sven Rohmann: trading record in brief

Sven Rohmann appears in our data through filings on Oasmia Pharmaceutical AB shares, published by Finansinspektionen. In total, 11 filings cover trades dated from 27 November 2019 to 18 June 2020.

Both buying and selling appear: 4 purchases worth €137k, against 6 sales worth €291k. Netting one side against the other leaves €155k of net selling. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. 2020 to date brings no purchases and 6 sales.

The median purchase comes to €29k.

The latest filing, published on 22 June 2020, reports an open-market sale of €59k in Oasmia Pharmaceutical AB. The last insider purchase was made public on 28 November 2019, 2,537 days ago. Between a trade and the moment it shows up on Finansinspektionen, the median delay is 4 days. The regulation allows three business days to notify a trade (MAR article 19). A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. This summary is built from Finansinspektionen disclosures alone and does not predict where the share price will go.

Companies and markets linked to Sven Rohmann

Open company profiles for insider transactions, fundamentals and analyst consensus when available.

Declarations11 total
  • ▼
    Board memberExecutivesOasmia Pharmaceutical AB
    620,638 SEK8FI-SE
    100,000 shares@ SEK 6.206410.4% of flowAktieISIN SE0000722365FI:csv-214eab4f135348da18ee
  • ▼
    Board memberExecutivesOasmia Pharmaceutical AB
    499,614 SEK8FI-SE
    80,000 shares@ SEK 6.24528.4% of flowAktieISIN SE0000722365FI:csv-6f08441e5ffaad28bf31
  • ▼
    Board memberExecutivesOasmia Pharmaceutical AB
    492,724 SEK8FI-SE
    77,000 shares@ SEK 6.3998.3% of flowAktieISIN SE0000722365FI:csv-8418b1bd2d9ef0d00ca2
  • ▼
    Board memberExecutivesOasmia Pharmaceutical AB
    476,657 SEK8FI-SE
    77,000 shares@ SEK 6.19048.0% of flowAktieISIN SE0000722365FI:csv-782c18fd8de62994868f
  • ▼
    Board memberExecutivesOasmia Pharmaceutical AB
    486,656 SEK8FI-SE
    77,000 shares@ SEK 6.32028.2% of flowAktieISIN SE0000722365FI:csv-458515ec33a171a1d239
  • ▼
    Board memberExecutivesOasmia Pharmaceutical AB
    504,703 SEK8FI-SE
    78,370 shares@ SEK 6.448.5% of flowAktieISIN SE0000722365FI:csv-ad6068a4e8448840f039
  • ●
    Board member and acting CEOExecutivesOasmia Pharmaceutical AB
    1M SEK0FI-SE
    720,000 shares@ SEK 2.0024.2% of flowBTA (betald tecknad aktie)ISIN SE0013460557FI:csv-5a2fa2ce2c3310df5cea
  • ▲
    Board member and acting CEOExecutivesOasmia Pharmaceutical AB
    436,195 SEK0FI-SE
    300,000 shares@ SEK 1.4547.3% of flowTeckningsrättISIN SE0013460540FI:csv-9331a427a61723019a6d
    Canonical exit: 25 Feb 2020 (T+90)
  • ▲
    Board member and acting CEOExecutivesOasmia Pharmaceutical AB
    179,276 SEK0FI-SE
    110,528 shares@ SEK 1.6223.0% of flowTeckningsrättISIN SE0013460540FI:csv-3e0c94e94d8eb3410c3f
    Canonical exit: 25 Feb 2020 (T+90)
  • ▲
    Board member and acting CEOExecutivesOasmia Pharmaceutical AB
    665,733 SEK0FI-SE
    400,000 shares@ SEK 1.664311.2% of flowTeckningsrättISIN SE0013460540FI:csv-a3f76f4f880df9a6859c
    Canonical exit: 25 Feb 2020 (T+90)
  • ▲
    Board member and acting CEOExecutivesOasmia Pharmaceutical AB
    164,096 SEK0FI-SE
    89,472 shares@ SEK 1.8342.8% of flowTeckningsrättISIN SE0013460540FI:csv-ddbcf57770c155f92900
    Canonical exit: 25 Feb 2020 (T+90)

11 of 11 declarations